Mammalian Cell Transfection: Methods and Optimization | Biology

Stable transfection achieves permanent foreign DNA integration into the host genome, enabling long-term expression across cell generations. This process is significantly more challenging, occurring in approximately 1 in 10,000 cells. Scientists employ selection strategies using antibiotic resistance genes to identify successfully transfected cells; only those with integrated DNA survive antibiotic treatment. Linear DNA is preferred over circular DNA for stable transfection. Unlike transient methods where expression degrades over time, stable transfection maintains foreign DNA expression indefinitely in descendant cell populations.

This video demonstrates the selection procedure for generating stable transfected cell lines using limited dilution cloning. After transfection, cells are detached and resuspended in 10% conditioned selection medium containing the appropriate antibiotic concentration determined from a kill curve. Cells are plated at low densities (1, 5, and 10 cells/mL) in 96-well plates and incubated at 37°C with 5% CO2. Wells are monitored under microscope for single-cell colony formation, which typically appears within 3-7 days depending on cell proliferation rate. When colonies reach confluence, they are expanded sequentially from 96-well plates to 24-well plates and finally to culture flasks with selection medium until sufficient cells are obtained for freeze-down and experiments.

This section covers strategies for generating stable cell lines for therapeutic protein production. Key topics include: (1) bulk pool selection using DG44 cells (lacking DHFR gene) where only transfected cells survive in unsupplemented media; (2) mini pool workflows seating ~2,000 cells per well to identify wells with predominantly high-expressing clones; (3) progressive selection including methotrexate amplification and single-cell cloning; (4) generating high-yielding stable clones within three months; (5) benefits of high viability post-electroporation enabling rapid selection and expansion within 3 weeks compared to methods with lower viability that prolong recovery periods.

After receiving signals 1 and 2, T cells differentiate into Th2 cells expressing CD40. CD40-CD40L interaction provides signal 2, causing clonal expansion through T cell proliferation. Th2 cells secrete IL-6 and other cytokines that support B cell proliferation. Only cells with high-affinity receptors and rapid activation survive; others undergo apoptosis.

After cell fusion, not all hybridomas survive. HAT medium (hypoxanthine, aminopterin, thymidine) is used to select hybridomas by blocking the de novo nucleotide synthesis pathway in myeloma cells. Only hybridomas that can use the salvage pathway (inherited from B cells) survive. The surviving hybridomas undergo clonal expansion through mitosis, increasing in number while producing identical monoclonal antibodies.

This webinar presents the development of NanoMEDIC, a novel CRISPR-Cas9 delivery platform using extracellular vesicles produced by flow electroporation in suspension culture, which enables scalable, transient delivery of Cas9 ribonucleoproteins with reduced off-target effects compared to viral vector delivery; the system utilizes chemical ligand-induced dimerization for Cas9 packaging and self-cleaving ribozymes for guide RNA incorporation, achieving efficient genome editing in difficult-to-transfect cells including human induced pluripotent stem cells and demonstrating successful in vivo application in a luciferase reporter mouse model.

This section covers the complete workflow from guide RNA ordering to ribonucleoprotein complex assembly. Researchers order 20-base DNA sequences (converted to RNA format) along with universal tracer RNA and Cas9 nuclease. Assembly involves resuspending RNAs in appropriate buffer, mixing CR RNA with tracer RNA at 1:1 molar ratio, heating to denature secondary structures, cooling to form duplexes, then combining with Cas9 nuclease at 1:1 ratio. This process takes under one hour. Three delivery methods exist: lipofection (simplest, high-throughput), electroporation (better for challenging cells like primary cells and iPSCs), and microinjection (model organism applications).

Invitro transcribed RNAs trigger innate immune responses, inducing interferon-stimulated genes 500-fold compared to minimal induction with synthetic two-part RNAs. Protospacer length optimization showed 17-nucleotide versions significantly reduced on-target activity while potentially decreasing off-target effects. Direct delivery of Cas9 protein complexed with guide RNA as ribonucleoprotein (RNP) complexes offers superior advantages: RNA protection from degradation, higher editing efficiency than plasmid delivery, no DNA integration events, tight temporal control of Cas9 expression, reduced off-target effects from excess Cas9, and reduced mosaicism risk. RNP delivery achieves comparable efficiencies to stable Cas9 cell lines while enabling diverse cell type applications including primary cells and embryos.

This section covers CRISPR delivery methods and vector systems. CRISPR systems must be delivered into cells and transported to the nucleus to function. Main delivery methods include: (1) Plasmid DNA - large circular DNA molecules (about 10 kilobases) encoding Cas proteins and guide RNAs, propagated in bacteria and transfected into target cells; (2) Viral vectors - lentiviral (integrates into genome, widely used), adenoviral (doesn't integrate, preferred for therapy), and AAV (small, good tissue specificity) vectors that package CRISPR components; (3) Ribonucleoprotein complexes - pre-assembled Cas protein and guide RNA complexes that can be directly delivered; (4) Exosome-based delivery - extracellular vesicles that naturally fuse with target cell membranes. Transfection methods include electroporation, lipofection, and AGRABACTERIAL TRANSFORMATION for plants. Plasmid vectors contain bacterial origins, promoters (U6 or H1), spacer sequences, Cas protein coding sequences, and reporter genes for selection. Two-vector systems separate Cas protein and guide RNA into different plasmids, allowing independent optimization.

This video demonstrates the RNP transfection method for gene editing human induced pluripotent stem cells (iPSCs), where Cas9 protein and CRISPR RNA are complexed together and delivered via electroporation using the Neon system; the protocol involves preparing Cas9 and CRISPR RNA at 10 micromolar concentrations, aliquoting cells at 1.04 million per tube, pelleting cells at 211 x g for 3 minutes, resuspending in R buffer, mixing with RNP complexes, and electroporating with program 8, followed by overnight incubation and media change the next day.

This section establishes the foundation for understanding viral vector production in cell and gene therapy. Mirus Bio's transfection technology combines cationic lipids and polymers, distinguishing it from competitors using only PEI or only liposomes. Lentivirus enables genetic modification of patient cells for immunotherapies like CAR-T cells, while AAV serves as direct gene therapy vectors. With over 1,000 therapies in development and 60% using lentivirus or AAV, efficient production is critical. Key optimization parameters include total DNA amount (1.5-2 μg/ml for lentivirus, 1.5-2 μg/ml for AAV) and cell density (2-4 million cells/ml depending on enhancer use). Systematic titration of these parameters is essential because optimal conditions depend on interactions between vectors, cells, and media. Standardized workflows for lentivirus and AAV production follow consistent protocols adapted for each vector type, with complex formation stability allowing flexibility for industrial manufacturing.

AAV vectors represent 50% of gene therapy strategies due to 30+ serotypes with tunable tropism. Manufacturing requires optimizing plasmid design, producer cell selection (HEK 293 or SF9 insect cells), and choosing between transient/stable production systems. The bioproduction workflow includes upstream cell culture, transfection, harvest, and downstream purification/concentration. Scaling from small-scale to industrial production (minimum 50L) requires parameter optimization and proof of equivalent quality. This gap between preclinical research and clinical manufacturing remains a significant challenge for widespread gene therapy implementation.

Cell and gene therapies utilize viral vectors (lentivirus and AAV) to deliver therapeutic genes directly to patient cells. Gene therapy packages transgenes within viruses for administration, treating conditions like spinal muscular atrophy, retinal diseases, hemophilia, and Parkinson's. Cell therapy uses engineered cells manipulated with lentiviral vectors to attack diseased cells like cancer. Currently, two FDA-approved AAV therapies exist (Lumacera, Zolgensma), and four FDA-approved lentivirus cell therapies (Kymriah, Yescarta, Tisagenlecleucel, Breyanzi). The field evolved through two phases: initial studies used adherent cell culture but faced scalability limits. The current phase demands 100-1000 fold greater capacity, higher patient doses, and larger patient populations (10,000-100,000 patients per indication), driving the industry toward suspension cell culture for scalability and higher yields.

Gene therapy manufacturing faces significant scalability challenges because university-developed viral vector production methods, while suitable for small clinical batches, cannot efficiently scale up for commercial production; CEVEC addresses this by developing a suspension-based cell culture platform using stable cell lines that carry all necessary genetic information for AAV vector production, eliminating the need for repeated transfection and enabling scalable bioreactor manufacturing similar to established antibody production processes.

Two main types of modified viruses are used as vectors in gene therapy: lentiviruses and adeno-associated viruses (AAV). Lentiviruses are derived from HIV but are inactivated and modified so they cannot replicate while still retaining their ability to infect cells. They are particularly effective for bone marrow and hematological conditions. AAVs are non-infectious but can efficiently infect cells and are used for cardiac diseases as well as neurological and liver conditions. The choice of vector depends on the target organ and its tropism characteristics.